CYTKNasdaqPharmaceutical PreparationsFiscal year ends December 31
CYTOKINETICS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$62.65+0.70 (+1.13%)
Close on Oct 19, 2026
- Market cap
- $8.28M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
160M of 139M shares
Institutional holders
482
95 new, 47 sold out
Net institutional buying
14M
In Q2 2026
Insider trades, 12 months
0 buys · 83 sales
Net sold $51.16M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Wellington Management Group LLP | 7,116,724 | 5.10% | 13G (passive) amendment | Jun 30, 2026 |
| Vanguard Capital Management | 6,422,042 | 5.21% | 13G (passive) | Mar 31, 2026 |
| T. Rowe Price Investment Management, Inc. | 17,716,372 | 14.50% | 13G (passive) amendment | Dec 31, 2025 |
| BlackRock, Inc. | 15,252,905 | 13.00% | 13G (passive) amendment | Sep 30, 2024 |
| FMR LLC | 13,101,596 | 10.90% | 13G (passive) amendment | Jul 31, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CYTK | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 20,094,362 | 14.45% | $1.71B | +3,546,351 | 0.03% |
| T. Rowe Price Investment Management, Inc. | 18,718,498 | 13.46% | $1.59M | +1,194,658 | 1.05% |
| Wellington Management Group Llp | 6,931,770 | 4.99% | $590.52M | −1,077,719 | 0.10% |
| Vanguard Portfolio Management LLC | 6,711,799 | 4.83% | $571.78M | +868,017 | 0.03% |
| State Street Corp | 6,494,233 | 4.67% | $553.24M | +749,040 | 0.02% |
| Vanguard Capital Management LLC | 6,117,515 | 4.40% | $521.15M | +628,881 | 0.01% |
| FMR LLC | 5,031,782 | 3.62% | $428.66M | −5,691,358 | 0.02% |
| Avoro Capital Advisors LLC | 4,999,999 | 3.60% | $425.95M | +1,666,666 | 3.82% |
| Bank Of America Corp /De/ | 4,635,709 | 3.33% | $394.92M | +1,510,273 | 0.03% |
| Geode Capital Management, LLC | 3,712,501 | 2.67% | $316.33M | +497,086 | 0.02% |
| Rtw Investments, LP | 2,862,003 | 2.06% | $243.81M | +140,845 | 2.08% |
| Polar Capital Holdings Plc | 2,253,649 | 1.62% | $191.99M | +592,401 | 0.45% |
| Price T Rowe Associates Inc /Md/ | 1,958,946 | 1.41% | $166.88K | +374,625 | 0.02% |
| Goldman Sachs Group Inc | 1,761,588 | 1.27% | $150.07M | −444,170 | 0.01% |
| Capital Research Global Investors | 1,686,625 | 1.21% | $143.68M | +915,626 | 0.02% |
| Northern Trust Corp | 1,647,345 | 1.18% | $140.34M | +205,711 | 0.02% |
| William Blair Investment Management, LLC | 1,603,442 | 1.15% | $136.60M | +515,851 | 0.41% |
| Integral Health Asset Management, LLC | 1,600,000 | 1.15% | $136.30M | – | 5.38% |
| JPMorgan Chase & Co | 1,588,895 | 1.14% | $139.15M | +685,090 | 0.01% |
| Point72 Asset Management, L.P. | 1,587,712 | 1.14% | $135.26M | +961,610 | 0.15% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 482 | 160M | 100.0% | 95 / 235 | 103 / 47 | 32M | 17M |
| Q1 2026 | 440 | 146M | 100.0% | 80 / 176 | 134 / 64 | 32M | 22M |
| Q4 2025 | 431 | 149M | 100.0% | 106 / 145 | 132 / 47 | 20M | 14M |
| Q3 2025 | 380 | 142M | 100.0% | 101 / 126 | 103 / 26 | 17M | 12M |
| Q2 2025 | 311 | 138M | 99.1% | 28 / 144 | 103 / 71 | 19M | 18M |
| Q1 2025 | 355 | 136M | 98.1% | 56 / 141 | 109 / 44 | 14M | 9M |
| Q4 2024 | 346 | 131M | 94.5% | 48 / 118 | 136 / 47 | 12M | 18M |
| Q3 2024 | 348 | 138M | 99.0% | 47 / 144 | 97 / 41 | 27M | 12M |
| Q2 2024 | 344 | 137M | 98.3% | 43 / 156 | 93 / 85 | 31M | 15M |
| Q1 2024 | 389 | 121M | 86.7% | 104 / 127 | 121 / 61 | 33M | 30M |
| Q4 2023 | 347 | 119M | 85.5% | 122 / 76 | 107 / 23 | 23M | 14M |
| Q3 2023 | 250 | 110M | 79.1% | 26 / 95 | 78 / 27 | 9M | 7M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of CYTK | Value | % of fund | As of |
|---|---|---|---|---|---|
| T. Rowe Price Capital Appreciation Fund | 6,285,983 | 4.52% | $535.50M | 0.76% | Jun 30, 2026 |
| iShares Core S&P Mid-Cap ETF | 4,646,338 | 3.34% | $395.82M | 0.32% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 4,314,356 | 3.10% | $367.54M | 0.02% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 3,394,982 | 2.44% | $289.22M | 0.35% | Jun 30, 2026 |
| Vanguard Health Care Fund | 3,341,262 | 2.40% | $257.71M | 0.68% | Jul 31, 2026 |
| Vanguard Small-Cap Index Fund | 3,114,802 | 2.24% | $265.35M | 0.14% | Jun 30, 2026 |
| SMALLCAP World Fund Inc | 2,997,051 | 2.16% | $255.32M | 0.27% | Jun 30, 2026 |
| Fidelity OTC Portfolio | 2,269,700 | 1.63% | $175.06M | 0.41% | Jul 31, 2026 |
| T. Rowe Price Mid-Cap Growth Fund, Inc. | 1,972,209 | 1.42% | $168.01M | 0.73% | Jun 30, 2026 |
| Vanguard Small-Cap Growth Index Fund | 1,793,318 | 1.29% | $152.77M | 0.32% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,557,317 | 1.12% | $132.67M | 0.14% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 1,484,466 | 1.07% | $126.46M | 1.18% | Jun 30, 2026 |
| JNL/T. Rowe Price Capital Appreciation Fund | 1,446,059 | 1.04% | $123.19M | 0.81% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 1,444,620 | 1.04% | $111.42M | 0.33% | Jul 31, 2026 |
| T. Rowe Price Capital Appreciation Equity ETF | 1,160,888 | 0.84% | $98.90M | 1.34% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Robert I. Blum | President & CEO, Director | 282,710 | 0.20% | Sep 28, 2026 |
| Fady Ibraham Malik | EVP Research & Development | 153,902 | 0.11% | Sep 22, 2026 |
| Andrew Callos | EVP, Chief Commercial Officer | 58,555 | 0.04% | Aug 31, 2026 |
| Sung Lee | EVP, Chief Financial Officer | 63,221 | 0.05% | Jul 2, 2026 |
| Jeffrey Hessekiel | Chief Legal & Admin Officer | 107,943 | 0.08% | Mar 17, 2026 |
| Robert Wong | VP, Chief Accounting Officer | 17,889 | 0.01% | Dec 5, 2024 |
| Robert E. Landry | Director | 8,184 | 0.01% | Sep 15, 2026 |
| B. Lynne Parshall | Director | 10,784 | 0.01% | Sep 1, 2026 |
| James M. Daly | Director | 3,390 | 0.00% | Jul 16, 2026 |
| Nancy Wysenski | Director | 33,992 | 0.02% | Jul 16, 2026 |
| Edward M. Kaye MD | Director | 10,434 | 0.01% | Jul 16, 2026 |
| Robert Arthur Harrington | Director | 21,932 | 0.02% | Jul 16, 2026 |
| John T. Henderson | Director | 78,443 | 0.06% | Jul 16, 2026 |
| Wendell Wierenga | Director | 35,563 | 0.03% | Jul 16, 2026 |
| Muna Bhanji | Director | 26,361 | 0.02% | May 27, 2026 |
| Wendall Wierenga | Director | 32,345 | 0.02% | Jul 16, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Robert I. Blum President & CEO, Director | Sep 28, 2026 | Sale(10b5-1 plan) | −7,500 | $65.46 | $490.95K | 278,544 |
| Robert I. Blum President & CEO, Director | Sep 28, 2026 | Option exercise | +7,500 | $10.60 | $79.50K | 286,044 |
| Fady Ibraham Malik EVP Research & Development | Sep 22, 2026 | Sale(10b5-1 plan) | −3,500 | $68.29 | $239.02K | 153,902 |
| Fady Ibraham Malik EVP Research & Development | Sep 22, 2026 | Option exercise | +3,500 | $7.80 | $27.30K | 157,402 |
| Robert E. Landry Director | Sep 15, 2026 | Sale(10b5-1 plan) | −1,000 | $72.13 | $72.13K | 8,184 |
| Robert I. Blum President & CEO, Director | Sep 15, 2026 | Sale(10b5-1 plan) | −97,926 | $69.33 | $6.79M | 0 |
| Robert I. Blum President & CEO, Director | Sep 14, 2026 | Gift | +97,926 | – | – | 97,926 |
| Robert I. Blum President & CEO, Director | Sep 14, 2026 | Gift | −97,926 | – | – | 278,544 |
| Robert I. Blum President & CEO, Director | Sep 14, 2026 | Gift | −1,350 | – | – | 376,470 |
| Robert I. Blum President & CEO, Director | Sep 14, 2026 | Sale(10b5-1 plan) | −7,500 | $73.44 | $550.80K | 377,820 |
| Robert I. Blum President & CEO, Director | Sep 14, 2026 | Option exercise | +7,500 | $10.60 | $79.50K | 385,320 |
| Robert E. Landry Director | Sep 11, 2026 | Sale(10b5-1 plan) | −1,000 | $74.66 | $74.66K | 9,184 |
| Fady Ibraham Malik EVP Research & Development | Sep 8, 2026 | Sale(10b5-1 plan) | −3,500 | $75.46 | $264.11K | 153,902 |
| Fady Ibraham Malik EVP Research & Development | Sep 8, 2026 | Option exercise | +3,500 | $7.80 | $27.30K | 157,402 |
| B. Lynne Parshall Director | Sep 1, 2026 | Sale(10b5-1 plan) | −5,000 | $71.48 | $357.40K | 10,784 |
| Robert I. Blum President & CEO, Director | Aug 31, 2026 | Option exercise | +7,500 | $10.60 | $79.50K | 385,320 |
| Robert I. Blum President & CEO, Director | Aug 31, 2026 | Sale(10b5-1 plan) | −7,500 | $70.24 | $526.80K | 377,820 |
| Andrew Callos EVP, Chief Commercial Officer | Aug 31, 2026 | Sale(10b5-1 plan) | −10,000 | $70.24 | $702.40K | 58,555 |
| Andrew Callos EVP, Chief Commercial Officer | Aug 31, 2026 | Option exercise | +10,000 | $23.26 | $232.60K | 68,555 |
| Fady Ibraham Malik EVP Research & Development | Aug 18, 2026 | Sale(10b5-1 plan) | −3,500 | $75.82 | $265.37K | 153,902 |
| Fady Ibraham Malik EVP Research & Development | Aug 18, 2026 | Option exercise | +3,500 | $7.80 | $27.30K | 157,402 |
| Robert I. Blum President & CEO, Director | Aug 10, 2026 | Sale(10b5-1 plan) | −7,500 | $76.76 | $575.70K | 377,820 |
| Robert I. Blum President & CEO, Director | Aug 10, 2026 | Option exercise | +7,500 | $10.60 | $79.50K | 385,320 |
| Andrew Callos EVP, Chief Commercial Officer | Jul 30, 2026 | Sale(10b5-1 plan) | −14,000 | $79.88 | $1.12M | 58,555 |
| Andrew Callos EVP, Chief Commercial Officer | Jul 30, 2026 | Option exercise | +14,000 | $23.26 | $325.64K | 72,555 |
| Robert I. Blum President & CEO, Director | Jul 27, 2026 | Sale(10b5-1 plan) | −7,500 | $80.87 | $606.53K | 377,820 |
| Robert I. Blum President & CEO, Director | Jul 27, 2026 | Option exercise | +7,500 | $10.60 | $79.50K | 385,320 |
| Fady Ibraham Malik EVP Research & Development | Jul 21, 2026 | Sale(10b5-1 plan) | −3,500 | $80.59 | $282.07K | 153,902 |
| Fady Ibraham Malik EVP Research & Development | Jul 21, 2026 | Option exercise | +3,500 | $7.80 | $27.30K | 157,402 |
| Edward M. Kaye MD Director | Jul 15, 2026 | Award | +151 | $82.62 | $12.48K | 10,434 |
| James M. Daly Director | Jul 15, 2026 | Award | +151 | $82.62 | $12.48K | 3,390 |
| Robert Arthur Harrington Director | Jul 15, 2026 | Award | +151 | $82.62 | $12.48K | 21,932 |
| Wendell Wierenga Director | Jul 15, 2026 | Award | +75 | $82.62 | $6.20K | 35,563 |
| Nancy Wysenski Director | Jul 15, 2026 | Award | +75 | $82.62 | $6.20K | 33,992 |
| John T. Henderson Director | Jul 15, 2026 | Award | +272 | $82.62 | $22.47K | 78,360 |
| Robert I. Blum President & CEO, Director | Jul 13, 2026 | Option exercise | +7,490 | $10.60 | $79.39K | 385,310 |
| Robert I. Blum President & CEO, Director | Jul 13, 2026 | Sale(10b5-1 plan) | −7,490 | $82.02 | $614.33K | 377,820 |
| Robert I. Blum President & CEO, Director | Jul 13, 2026 | Sale(10b5-1 plan) | −10 | $82.02 | $820 | 377,820 |
| Fady Ibraham Malik EVP Research & Development | Jul 7, 2026 | Option exercise | +3,500 | $7.80 | $27.30K | 157,402 |
| Fady Ibraham Malik EVP Research & Development | Jul 7, 2026 | Sale(10b5-1 plan) | −3,500 | $86.62 | $303.17K | 153,902 |
| Robert I. Blum President & CEO, Director | Jul 1, 2026 | Sale(10b5-1 plan) | −7,500 | $84.92 | $636.90K | 377,830 |
| Sung Lee EVP, Chief Financial Officer | Jul 1, 2026 | Sale(10b5-1 plan) | −1,112 | $87.79 | $97.62K | 63,221 |
| Sung Lee EVP, Chief Financial Officer | Jul 1, 2026 | Option exercise | +1,112 | $48.51 | $53.94K | 64,333 |
| Andrew Callos EVP, Chief Commercial Officer | Jul 1, 2026 | Option exercise | +15,000 | $23.26 | $348.90K | 73,555 |
| Andrew Callos EVP, Chief Commercial Officer | Jul 1, 2026 | Sale(10b5-1 plan) | −15,000 | $85.80 | $1.29M | 58,555 |
| Sung Lee EVP, Chief Financial Officer | Jun 29, 2026 | Option exercise | +1,113 | $48.51 | $53.99K | 65,344 |
| Sung Lee EVP, Chief Financial Officer | Jun 29, 2026 | Option exercise | +823 | $44.36 | $36.51K | 66,355 |
| Sung Lee EVP, Chief Financial Officer | Jun 29, 2026 | Option exercise | +188 | $44.36 | $8.34K | 65,532 |
| Sung Lee EVP, Chief Financial Officer | Jun 29, 2026 | Sale(10b5-1 plan) | −3,134 | $85.00 | $266.39K | 63,221 |
| Sung Lee EVP, Chief Financial Officer | Jun 29, 2026 | Option exercise | +822 | $44.36 | $36.46K | 64,231 |
| Sung Lee EVP, Chief Financial Officer | Jun 29, 2026 | Option exercise | +188 | $44.36 | $8.34K | 63,409 |
| Sung Lee EVP, Chief Financial Officer | Jun 24, 2026 | Option exercise | +188 | $44.36 | $8.34K | 100,016 |
| Sung Lee EVP, Chief Financial Officer | Jun 24, 2026 | Option exercise | +1,113 | $48.51 | $53.99K | 101,951 |
| Sung Lee EVP, Chief Financial Officer | Jun 24, 2026 | Option exercise | +822 | $44.36 | $36.46K | 100,838 |
| Sung Lee EVP, Chief Financial Officer | Jun 24, 2026 | Option exercise | +1,113 | $48.51 | $53.99K | 99,828 |
| Sung Lee EVP, Chief Financial Officer | Jun 24, 2026 | Sale(10b5-1 plan) | −38,730 | $82.30 | $3.19M | 63,221 |
| Sung Lee EVP, Chief Financial Officer | Jun 24, 2026 | Option exercise | +2,817 | $44.36 | $124.96K | 98,715 |
| Sung Lee EVP, Chief Financial Officer | Jun 24, 2026 | Option exercise | +9,307 | $44.36 | $412.86K | 95,898 |
| Sung Lee EVP, Chief Financial Officer | Jun 24, 2026 | Option exercise | +23,370 | $48.51 | $1.13M | 86,591 |
| Fady Ibraham Malik EVP Research & Development | Jun 23, 2026 | Option exercise | +3,500 | $7.80 | $27.30K | 157,402 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Blum Robert Director, Officer | Oct 13, 2026 | 22,500 | $1.42M | Oct 12, 2026 | Exercise of Stock Options |
| I. Blum Robert President, CEO, Director | Sep 15, 2026 | 97,926 | $7.09M | Sep 15, 2026 | Transfer |
| Landry Robert Director | Sep 11, 2026 | 2,000 | $147.24K | Sep 11, 2026 | Restricted Stock Units |
| Lynne Parshall B Director | Sep 1, 2026 | 5,000 | $354.55K | Sep 1, 2026 | Restricted Stock Units |
| Callos Andrew Officer | Jul 30, 2026 | 24,000 | $1.88M | Jul 30, 2026 | Exercise of Stock Options |
| Malik Fady Officer | Jul 7, 2026 | 24,500 | $2.10M | Jul 7, 2026 | Exercise of Stock Options |
| Blum Robert Director, Officer | Jul 1, 2026 | 52,500 | $4.47M | Jul 1, 2026 | Exercise of Stock Options |
| Lee Sung Officer | Jun 29, 2026 | 9,503 | $781.05K | Jun 29, 2026 | Exercise of Stock Options |
| Lee Sung Officer | Jun 26, 2026 | 6,695 | $540.96K | Jun 26, 2026 | Restricted Stock Units |
| Lee Sung Officer | Jun 24, 2026 | 38,730 | $3.10M | Jun 24, 2026 | Exercise of Stock Options |
| Kaye Edward Director | Jun 1, 2026 | 2,933 | $225.14K | Jun 1, 2026 | Restricted Stock Units |
| Wierenga Wendell Director | May 5, 2026 | 4,032 | $266.31K | May 5, 2026 | Exercise of Stock Options |
| Henderson John Director | May 5, 2026 | 20,000 | $1.32M | May 5, 2026 | Exercise of Stock Options |
| Lee Sung Officer | May 5, 2026 | 23,906 | $1.58M | May 5, 2026 | Restricted stock units and performance stock units |
| Callos Andrew Officer | Apr 15, 2026 | 79,639 | $5.28M | Apr 15, 2026 | Exercise of Stock Options |